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Material and Methods: Retrospective review of all patients 
with T4 HNSCC treated with IMRT at our centre, between 
December 2010 and February 2013. Overall, relapse free and 
local relapse-free survival were calculated from date of 
biopsy to date of death, relapse or last follow up. 
 
Results: Of the 69 patients with T4 tumours, 73.9% were 
male and median age was 69 (41-84). 50.7% were 
oropharyngeal tumours and 73.9% were node positive. 
Primary resection was performed in 18 patients. Eighteen 
patients underwent radiotherapy alone and 51 received 
concurrent chemotherapy (45 cisplatin, 6 cetuximab). Median 
follow up was 3.0 years (range = 3 months to 3.9 years). 28 
patients died; 22 related to HNSCC, 6 from other causes. 
Overall survival at 3 years was 58.0% (95% CI: 44.6 to 69.1). 
28 patients (40.6%), relapsed with median time to relapse of 
8 months. 20 patients (29.0%) relapsed locoregionally and 11 
patients (15.9%) developed distant metastatic disease. For 8 
patients, distant metastases were the only site of relapse. 
Surgical salvage was performed in 6 patients with 
locoregional relapse only, 2 of whom have since died from 
causes related to HNSCC. Relapse free survival at 3 years was 
54.0% (95% CI: 40.5 to 65.8) and loco-regional relapse free 
survival at 3 years was 65.5% (95% CI: 51.2 to 76.5). Nineteen 
patients (27.5%) had residual disease on PET scan 12 weeks 
post treatment. These patients were at greater risk of 
relapse and death with 3 year overall survival of 37.0% (95% 
CI 15.4 to 59.0) and 3 year relapse free survival of 40.5% 
compared to 3 year overall survival of 85.7% (53.9 to 96.2) 
and 3 year relapse free survival of 79.0% (47.9 to 92.7) in 
patients with normal PET scans.  
 
Conclusion: There is a significant risk of relapse and death in 
T4 HNSCC tumours, particularly in those with residual disease 
following radiotherapy. However, IMRT, either alone or in 
combination with chemotherapy or surgery, achieved 3 year 
locoregional control of 65.5% (95% CI 51.2%-76.5%). This is a 
meaningful local control rate for locally advanced disease in 
which local relapse confers significant morbidity. 
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Purpose or Objective: To investigate the role of HPV status, 
comorbidity and polypharmacy on outcomes of elderly 
patient with oropharyngeal carcinoma (OPC). 
 
Material and Methods: We retrospectively reviewed a 
prospectively compiled cohort of elderly patients (>70 years) 
with newly diagnosed OPC treated with curative radiotherapy 
(RT)+/- systemic therapy in 2000-2013. Tumor HPV status was 
assessed by p16 staining. Comorbidities were quantified by 
Charlson Comorbidity Index (CCI). The Comorbidity-
Polypharmacy Score (CPS), a validated predictor of outcome 
for older trauma patients, was used to take into account the 
number of medications as a surrogate of the severity of 
comorbidities. Overall survival (OS), and relapse-free survival 
(RFS) were calculated and compared between HPV-positive 
[HPV(+)] and HPV-negative [HPV(-)] cohort. Two multivariate 
analysis (MVA) models [one included CCI (MVA-CCI), one 
included CPS (MVA-CPS)] were used to confirm the prognostic 
value of HPV, CCI or CPS, pack-year (PY) smoking, ECOG 
performance status (PS), and age for OS adjusted for disease 
extent (T, N). 
 
Results: Tumor HPV status was ascertained in 229 of 287 
(80%) patients revealing 115 HPV(+) and 114 HPV(-). Median 
age was 74.8 years (range 70-93). Systemic agents were given 
in 48 (21%) patients [chemo 17; EGFR inhibitor 31). RT 
incompletion [5 (4%) vs 8 (7%), p=0.41) and unplanned RT 
break rates [22 (19%) vs 28 (25%), p=0.34] were similar 
between HPV(+) vs HPV(-) cohorts. No significant difference 
in distribution of CCI (p=0.30) or CPS score (p=0.22) between 
HPV(+) vs HPV(-) cases. CCI and CPS have a moderate 
correlation (Kappa: 0.51). Median follow-up was 4.6 years. 
HPV(+) patients had better 5-year OS (59% vs 32%, p<0.001) 
and RFS (75% vs 54%, p<0.001) compared to HPV(-). MVA 
adjusted for T and N-category confirmed HPV(+) status was 
the strongest prognostic factor (PF) for OS [MVA-CCI: HR 0.52 
(95% CI 0.34-0.79), p=0.002; MVA-CPS: HR 0.56 (0.36-0.85), 
p=0.007]. CPS was also a PF for OS [HR 1.05 (1.00-1.11), 
p=0.044]. CCI was not significant (p=0.17). ECOG PS was also 
a PF [MVA-CCI: HR 2.31; MVA-CPS: HR 2.32, both p<0.001]. 
Smoking (>20 PY) was prognostic in MVA-CCI (HR 1.62, 
p=0.035) and marginally prognostic in MVA-CPS (HR 1.56, 
p=0.056). Age was not significant in MVA-CCI (p=0.16) or 
MVA-CPS (p=0.65) models. 
 
Conclusion: In elderly patients with OPC, HPV status is a 
strong PF for OS. Neither chronologic age nor CCI is 
prognostic. Higher CPS is correlated with poorer OS, which 
implies that inclusion of polypharmacy in addition to 
comorbidity might be a better reflection of competing 
mortality risk in this population, and attention to competing 
mortality causes may influence outcome for this complex 
patient group. Further validation of prognostication of CPS in 
elderly OPC population is warranted. 
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Purpose or Objective: While the total tumor volume(TTV) 
has been extensively analyzed in literature as a prognostic 
factor in head and neck cancer, there exist no studies to date 
that have analysed the impact of TTV on response to chemo 
radiation(CCRT), particularly from the Indian subcontinent 
and in patients treated with IMRT. We did a prospective study 
that attempted to elucidate the role of total tumor volume 
as a prognostic factor in locally advanced oropharyngeal and 
hypopharyngeal cancer. 
 
Material and Methods: We enrolled 87 patients of Stage III-IV 
cancer of the oropharynx(57),and hypopharynx(30) , who 
received definitive CCRT with IMRT. The TTV was the sum of 
the gross tumour volume and the nodal volume delineated on 
the planning CT scan. The impact of TTV on Locoregional 
relapse free survival (LRFS), response to chemoradiation (RR) 
and overall survival (OS) was assessed over a follow up of 2 
years. Survival analysis was by kaplan meir method with log 
rank testing for assessing significance between groups 
Univariate analysis was by mann-whitney/chi square test 
,multivariate analysis was by logistic regression forward 
stepwise method and a model to predict response was 
generated .ROC curve analysis was done for calculating cut 
offs. A classification tree for Response was generated using 
CART analysis (CHAID method). 
 
Results: The 2 year OS, LRFS, and RR were 64%, 56% & 65%. 
The T stage distribution was T2(5) , T3(42) ,T4(42) & N stage 
was N0 (11),N1(28),N2A(10),N2B (17),N2C(17) & N3(4).The 
mean TTV was 67.4 cc (8-191 )cc. The mean TTV in 
Responders/ non responders was 51.9 cc / 95.5cc.On 
multivariate analysis, the TTV was a significant prognostic 
factor for RR & LRFS but not for OS. ROC curve analysis found 
cut off of 48 cc for RR with AUC of 0.778(0.672-0.884) ans 
sensitivity/specificity of 87% /60%.The RR for the <48cc and 
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>48cc group was 90% vs 46% (chi square p =.001). ROC curve 
analysis of our oropharyngeal subgroup revealed similar 
results with a cut off of 48cc with AUC of 0.802 (0.677-0.927) 
and sensitivity / specificity of 86%/70%.The RR for the <48cc 
and >48cc group was 88% vs 40% (chi square p =.001). The 
likelihood of not responding increased by 1.8%% for 1cc 
increase in TTV for the entire cohort and by 2.4% for our 
oropharyngeal subgroup. 
 
 
 
 
Conclusion: Our study shows that the TTV is a significant and 
independent prognostic factor in patients with locally 
advanced head and neck cancer in terms of predicting local 
control. Implications for existing management paradigms 
include, stratification according to TTV in future randomized 
trials and consideration of altered fractionation and/or dose 
escalation to the primary disease for patients with TTV>48cc.  
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Purpose or Objective: To evaluate the prognostic value of 
18F-FDG PET-CT performed prior to (prePET) and during the 
third week (iPET) of radiation therapy (RT) in patients with 
newly diagnosed nasopharyngeal carcinoma (NPC). 
 
Material and Methods: Thirty patients with newly diagnosed 
NPC treated with radical RT and Cisplatin-based 
chemotherapy underwent prePET and iPET. The median 
follow up was 26 months (range 8-66.9). AJCC staging 
included 12 patients in stage II, 8 in stage III and 10 in stage 
IV. The maximum standardised-uptake-value (SUVmax), 
metabolic-tumour-volume (MTV) and total-lesional-glycolysis 
(TLG) of primary tumour (PT), the index-node (IN) (defined as 
lymph node with highest TLG), total lymph nodes (TN) and 
combined primary tumour and nodal (PTN), and their % 
reductions in iPET were analysed, and results were correlated 
with 2-year loco-recurrence-free-survival (LRFS), regional-
failure-free-survival (RFFS), distant-metastatic-failure-free-
survival (DMFFS), disease-free-survival (DFS), and overall-
survival (OS), using Kaplan-Meier (KM) analysis. Optimal-
cutoffs (OC) were derived from Receiver-Operating-
Characteristic curves for the best combined sensitivity and 
specificity. 
 
Results: For LRFS, the only statistically significant predictor 
was reduction in primary tumour MTV by >50% in iPET (95.2% 
vs 75.0%, p=0.024). For other treatment outcomes, only 
nodal or combined PTN predicted treatment outcomes. The 
IN SUVmax (pre-PET OC=10.45g/mL and iPET OC=8.15g/mL) 
and TLG (pre-PET OC=90g and iPET OC=33.4g) provide the 
overall best predictor of outcome, with significant 
associations with RFFS (iPET only), DMFFS (prePET), DFS 
(prePET and iPET) and OS (prePET): For RFFS, iPET IN 
SUVmax and TLG were best predictors: the 2-year KM 
survivals were 100% vs. 50%, p<0.001 and 100% vs. 44%, 
p=0.032 respectively. For DMFFS, prePET IN SUVmax and TLG 
were best predictors: 100% vs. 51.9%, p=0.004 and 100% vs. 
47.6%, p=0.002. For DFS, prePET IN TLG and iPET IN SUVmax 
were best predictors: 87.5% vs. 33%, p=0.045 and 78.7% vs. 
20%, p=0.01. For OS, prePET IN TLG and iPET IN TLG were 
best predictors: 100% vs 72.7%, p=0.048 and 91.7% vs 68.6%, 
p=0.05. The IN metabolic parameters demonstrated stronger 
correlation with outcome than PT or PTN, and equivalent 
correlation to the TN except IN was better in predicting OS. 
 
Conclusion: The metabolic parameters of prePET and iPET 
can provide complementary prognostic biomarkers of patient 
outcomes, These parameters may have a role in adaptive 
therapy for NPC, and identifying the best treatment strategy 
for precision individualised chemo-radiotherapy 
combinations. We have demonstrated IN to be a useful novel 
imaging biomarker for predicting all treatment outcomes, 
and offers additional potential advantage of ease of 
generation and reproducibility compared to TN or PTN. 
 
EP-1096  
Prognostic value of pretreatment FDG-PET features in 
laryngeal cancer patients treated with RT 
R. Kabarriti
1Montefiore Medical Center- Albert Einstein College, 
Radiation Oncology, New York, USA 
1, P.N. Brodin1, A. Ginsburg Berkowitz1, A. 
Ingber1, N. Ohri1, K.P. McGovern1, C. Modi1, T.J. Ow2, A. 
Tassler2, S. Packer3, B.A. Schiff2, R.V. Smith2, M. Haigentz3, 
C. Guha1, S. Kalnicki1, W.A. Tomé1, M.K. Garg1 
2Montefiore Medical Center- Albert Einstein College, 
Otolaryngology- Head & Neck Surgery, New York, USA 
3Montefiore Medical Center- Albert Einstein College, Medical 
Oncology, New York, USA 
 
Purpose or Objective: Statistical image features from 
computed tomography (CT) and positron emission 
tomography (PET) scans are being investigated for the 
potential prognostic value in predicting outcome for various 
clinical indications. Here, we analyze primary tumor image 
features from pretreatment FDG-PET and the relation to 
clinical outcomes in patients treated with definitive radiation 
therapy (RT) for laryngeal cancer. 
 
Material and Methods: We identified 83 consecutive patients 
with laryngeal squamous cell carcinoma treated with 
definitive RT with available pretreatment PET/CT scans at 
our institution. Clinical variables related to disease and 
patient characteristics, treatment information, and clinical 
outcomes data were collected for each patient. Pretreatment 
PET/CT scans were used for image feature analysis of the 
primary tumor volume for each patient. Multiple statistical 
image features were computed, along with several measures 
related to the standardized uptake value (SUV). Redundant 
image features were excluded based on a strong correlation 
with parameters commonly reported as important such as 
metabolic tumor volume (MTV) and maximum SUV value 
(SUVmax). A LASSO procedure was applied to select 
appropriate variables to include in Cox proportional hazard 
models for local control (LC) progression-free survival (PFS) 
and overall survival (OS). The concordance index or “C-
index” was computed to evaluate the discriminative ability of 
each model, both on the training data set (apparent C-index) 
and using bootstrap cross-validation (bCV). Correction for 
